Trial reportJournal of diabetes science and technology2022
Mitigation of Rebound Hyperglycemia With Real-Time Continuous Glucose Monitoring Data and Predictive Alerts.
Trial report in Journal of diabetes science and technology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02671968 (Real-Time Continuous Glucose Monitoring), which is not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Real-Time Continuous Glucose Monitoring (RT-CGM) in Patients With Type 1 Diabetes at High Risk for Low Glucose Values Using Multiple Daily Injections (MDI) in Germany (HYPODE-STUDY)
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Systematic review of oral carbohydrate treatment for hypoglycemia in people living with type 2 diabetes mellitus.BMC endocrine disorders · 2026Pooled it
- Threshold and Predictive Alerts of Continuous Glucose Monitoring and Glycemic Control in Hospitalized Adults With Diabetes: A Randomized Clinical Trial.JAMA network open · 2026Trial
- Trial
- Systematic Review of Oral Carbohydrate Treatment for Non-Severe Hypoglycemia in Type 1 Diabetes: A Comparison of Insulin Management Systems.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Review
- Cost-Utility of Real-Time Continuous Glucose Monitoring Versus Self-monitoring of Blood Glucose in People with Insulin-Treated Type 2 Diabetes in Sweden.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- The Effect of 50% Dextrose on Serum Glucose Levels in Adult Hypoglycemic Patients: A Prospective Observational Study.Cureus · 2025Article
- Rebound Hypoglycemia and Hyperglycemia in Type 1 Diabetes.Journal of diabetes science and technology · 2024Article
- Insulinoma Unmasked: A Continuous Glucose Monitoring-Fueled Journey.Current oncology (Toronto, Ont.) · 2024Article
- Nocturnal Hypoglycemia in the Era of Continuous Glucose Monitoring.Journal of diabetes science and technology · 2024Review
- Integration of a Safety Module to Prevent Rebound Hypoglycemia in Closed-Loop Artificial Pancreas Systems.Journal of diabetes science and technology · 2024Article
- Glycemic variability through the perspective of the glycemia risk index and time in range and their association with glycated hemoglobin A1c in pediatric patients on sensor-augmented pump therapy.Frontiers in endocrinology · 2024Article
- Non-adjunctive continuous glucose monitoring for control of hypoglycaemia (COACH): Results of a post-approval observational study.Diabetic medicine : a journal of the British Diabetic Association · 2022Observational
- Characterization of Post-Hypoglycemic Hyperglycemia in Children and Adolescents With Type 1 Diabetes: The EPHICA Study.Frontiers in endocrinology · 2022Article
- Real-World Evidence and Glycemic Improvement Using Dexcom G6 Features.Diabetes technology & therapeutics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExcess carbohydrate intake during hypoglycemia can lead to rebound hyperglycemia (RH). We investigated associations between RH and use of real-time continuous glucose monitoring (rtCGM) and an rtCGM system's predictive alert.
methodsRH events were series of sensor glucose values (SGVs) >180 mg/dL starting within two hours of an antecedent SGV <70 mg/dL. Events were characterized by their frequency, duration (consecutive SGVs >180 mg/dL × five minutes), and severity (area under the glucose concentration-time curve). To assess the impact of rtCGM, data gathered during the four-week baseline phase (without rtCGM) and four-week follow-up phase (with rtCGM) from 75 participants in the HypoDE clinical trial (NCT02671968) of hypoglycemia-unaware individuals were compared. To assess the impact of predictive alerts, we identified a convenience sample of 24 518 users of an rtCGM system without predictive alerts who transitioned to a system whose predictive alert signals an SGV ≤55 mg/dL within 20 minutes (Dexcom G5 and G6, respectively). RH events from periods of blinded versus unblinded rtCGM wear and from periods of G5 and G6 wear were compared with paired t tests.
resultsCompared to RH events in the HypoDE baseline phase, the mean frequency, duration, and severity of events fell by 14%, 12%, and 23%, respectively, in the follow-up phase (all
conclusionsRebound hypreglycemia can be objectively quantified and mitigated with rtCGM and rtCGM-based predictive alerts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.